Display options
Share it on

Saudi Pharm J. 2014 Nov;22(5):472-82. doi: 10.1016/j.jsps.2013.12.004. Epub 2013 Dec 21.

Antioxidant and anti-inflammatory effects of Marrubium alysson extracts in high cholesterol-fed rabbits.

Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society

Soha S Essawy, Dina M Abo-Elmatty, Nabila M Ghazy, Jihan M Badr, Olov Sterner

Affiliations

  1. Department of Pharmacology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt.
  2. Department of Biochemistry, Faculty of Pharmacy, Suez Canal University, Ismailia, Egypt.
  3. Department of Pharmacognosy, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.
  4. Department of Natural Products and Alternative Medicine, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia ; Department of Pharmacognosy, Faculty of Pharmacy, Suez Canal University, Ismailia, Egypt.
  5. Department of Organic Chemistry 2, Lund University, P.O. Box 124, S-21100 Lund, Sweden.

PMID: 25473336 PMCID: PMC4246394 DOI: 10.1016/j.jsps.2013.12.004

Abstract

The antioxidant and anti-inflammatory effects of hexane (HEXA), chloroform (CHLORO), ethyl acetate (EA) and total alcoholic (T. ALCOH) extracts of Marrubium alysson in hypercholesterolemic-fed rabbits were evaluated. Hypercholesterolemia was induced in male rabbits by high cholesterol diet (HCD) (350 mg/kg) for 8 weeks. Hypercholesterolemic rabbits were allocated into groups, treated with simvastatin (SIM 5 mg/kg), different extracts of M. alysson at two doses of 250, 500 mg/kg. A normal control group and an HCD control one were used for comparison. Lipid profile, as well as oxidized low density lipoprotein-cholesterol (ox-LDL-C), myeloperoxidase activity (MPO) and superoxide anion production (O2•(-)), C-reactive protein (CRP) and monocyte chemoattractant protein-1 (MCP-1) were also evaluated. In addition, histological examination of ascending aorta was performed. We found dyslipidemia associated with significant increases in ox-LDL-C 123.5 ± 9.8 nmol MDA/mg non-HDL, MPO activity 0.08 ± 0.05 U/100 mg tissue and O2•(-) production 3.5 ± 0.3 nmol cytochrome C reduced/min/g tissue × 10(-4) in hypercholerterolemic rabbits. In addition, there was a significant increase in CRP 6.6 ± 0.49 μmol/L and MCP-1 190.9 ± 6.4 pg/ml and its mRNA expression in HCD. Intima appeared thick with thick plaques surrounding the intima and luminal narrowing. SIM, EA and HEXA extracts of M. alysson had lipid lowering effect, decrease in ox-LDL-C, MPO, O2•(-), CRP and MCP-1 mRNA expression with improvement of the pathological picture. M. alysson enhanced the stability of plaque, had lipid lowering, anti-inflammatory and antioxidant activities.

Keywords: Anti-inflammatory; Antioxidant; Hypercholesterolemia; Marrubium alysson

References

  1. J Pharmacol Exp Ther. 2007 Dec;323(3):794-804 - PubMed
  2. Phytochemistry. 1992 Oct;31(10):3624-6 - PubMed
  3. Toxicology. 1996 Sep 2;112(3):219-26 - PubMed
  4. Int J Cardiol. 2003 Aug;90(2-3):317-21 - PubMed
  5. Trends Cardiovasc Med. 2001 Apr-May;11(3-4):93-102 - PubMed
  6. JAMA. 2001 Jul 4;286(1):64-70 - PubMed
  7. Arterioscler Thromb Vasc Biol. 2009 Jan;29(1):33-9 - PubMed
  8. J Pharmacol Exp Ther. 2003 Apr;305(1):78-85 - PubMed
  9. J Pharm Pharmacol. 2011 Sep;63(9):1230-7 - PubMed
  10. Diabetes Care. 2005 Feb;28(2):379-84 - PubMed
  11. Am J Physiol Heart Circ Physiol. 2009 Dec;297(6):H2004-14 - PubMed
  12. Phytochemistry. 2005 May;66(9):1060-6 - PubMed
  13. Mol Nutr Food Res. 2005 Nov;49(11):995-8 - PubMed
  14. Eur Heart J. 2007 Mar;28(6):664-72 - PubMed
  15. Am J Med. 2004 Mar 22;116 Suppl 6A:9S-16S - PubMed
  16. Vasc Health Risk Manag. 2011;7:333-43 - PubMed
  17. Life Sci. 2001 Nov 2;69(24):2855-66 - PubMed
  18. J Immunol. 2002 Apr 15;168(8):4112-20 - PubMed
  19. Am J Cardiol. 1994 Jul 1;74(1):38-42 - PubMed
  20. Lipids Health Dis. 2005 Mar 04;4:6 - PubMed
  21. Chest. 2004 Apr;125(4):1483-91 - PubMed
  22. Cell Mol Biol (Noisy-le-grand). 2005 Sep 30;51(4):363-70 - PubMed
  23. J Cardiovasc Pharmacol. 1994 Mar;23(3):424-31 - PubMed
  24. Proc Natl Acad Sci U S A. 2003 Jun 10;100(12):7265-70 - PubMed
  25. Atherosclerosis. 2007 May;192(1):113-22 - PubMed
  26. N Engl J Med. 2005 Jan 6;352(1):20-8 - PubMed
  27. Nature. 2002 Dec 19-26;420(6917):868-74 - PubMed
  28. Thromb Res. 2009 Sep;124(4):458-62 - PubMed
  29. J Pharm Pharmacol. 2005 Feb;57(2):197-203 - PubMed
  30. Science. 2005 Jan 21;307(5708):366-7 - PubMed
  31. J Biomed Biotechnol. 2012;2012:506159 - PubMed
  32. Am J Pathol. 2001 Aug;159(2):457-63 - PubMed
  33. Arch Biochem Biophys. 2011 Feb 1;506(1):48-57 - PubMed
  34. J Am Coll Cardiol. 2006 Apr 4;47(7):1379-81 - PubMed
  35. Phytochemistry. 2003 Sep;64(2):655-60 - PubMed
  36. Cardiovasc Res. 2003 Jan;57(1):168-77 - PubMed
  37. N Engl J Med. 2000 Mar 23;342(12):836-43 - PubMed
  38. Am J Cardiol. 2006 Dec 4;98(11A):18P-25P - PubMed
  39. Genome Biol. 2007;8(9):R200 - PubMed

Publication Types